KXTbio is a biotechnology company focused on providing three product lines: i) high-quality reagents, ii) small molecule modulators and reporters, and iii) research-based kits. KXTbio will target customers from academic institutions, biotech, pharmaceutical companies, and contract research organizations (CROs). All products address unmet needs for researchers around the globe, particularly those who study the pharmacologically relevant class of G-protein-coupled receptors (GPCRs) and key proteins downstream of GPCRs, including, heterotrimeric G proteins, small guanosine triphosphates (GTPases), and their effectors. GPCRs have been important for drug discovery for years and are among the most investigated drug targets in the pharmaceutical industry. In contrast, the components downstream of GPCRs have only recently been exploited and represent significant future growth potential for the company. KXTbio is positioned to capitalize on both the GPCR and downstream market opportunities by providing high quality reagents and research tools.

• 2012: Company founding
• 2013: Winning of GSK drug screening award
• 2015: Distribution agreement with Cube Biotech
• 2016: Secured growth financing